A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks ...

Mr. Camburn, a former Novartis sales executive, claims the company used speaker events and excessive compensation to influence doctors' prescribing practices, violating the Antitrust Kickback Statute.

Recent health developments include a new injectable cancer drug by Bristol Myers Squibb, a revived lawsuit against Novartis ...

Novartis (NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma met its primary endpoint in ...

Recent health developments include the FDA's approval of an injectable version of Bristol Myers Squibb's cancer drug Opdivo.

Novartis (NVS) announced positive topline results from the Phase 3 STEER study. This pivotal study assessed the efficacy and safety of investigational intrathecal onasemnogene abeparvovec in ...

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed. The case furthe ...

Novartis and its lawyers did not respond to requests for comment. The False Claims Act lets whistleblowers sue on behalf of the government, and share in recoveries. Friday's decision vacated a ...